OnKure Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 10, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 10, 2025
OKUR$3.39+6.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows
(In thousands)
| Years Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| (in thousands) | ||
| Cash flows from operating activities: | ||
| Net loss | $(52,673) | $(35,311) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Share-based compensation expense | 4,530 | 199 |
| Depreciation and amortization | 459 | 417 |
| Amortization of right-of-use asset - operating | 203 | 143 |
| Amortization of debt issuance costs | 142 | — |
| Non-cash interest expense | 120 | — |
| Loss on sales of available-for-sale securities | 54 | — |
| Change in operating assets and liabilities: | ||
| Prepaid and other assets | 2,256 | (1,497) |
| Accounts payable, accrued and other liabilities | (5,927) | 1,713 |
| Lease liabilities | (281) | (210) |
| Net cash used in operating activities | (51,117) | (34,546) |
| Cash flows from investing activities: | ||
| Proceeds from sales of marketable securities | 15,925 | — |
| Purchases of property and equipment | (52) | (246) |
| Net cash provided by (used in) investing activities | 15,873 | (246) |
| Cash flows from financing activities: | ||
| Proceeds from the issuance of common stock in Concurrent Financing | 58,881 | — |
| Payment of issuance costs associated with the Concurrent Financing | (4,327) | — |
| Cash acquired in connection with the reverse recapitalization | 57,736 | — |
| Payment of reverse recapitalization transaction costs | (2,045) | — |
| Proceeds from the issuance of Convertible Preferred Stock | — | 53,783 |
| Payment of issuance costs associated with the issuance of Convertible Preferred Stock | — | (723) |
| Proceeds from issuance of convertible notes payable | 6,000 | — |
| Payment of issuance costs associated with the issuance of convertible notes payable | (142) | — |
| Proceeds from the issuance of common stock in connection with equity plans | 26 | 65 |
| Net cash provided by financing activities | 116,129 | 53,125 |
| Net increase in cash and cash equivalents | 80,885 | 18,333 |
| Cash and cash equivalents, beginning of period | 29,876 | 11,543 |
| Cash and cash equivalents, end of period | $110,761 | $29,876 |
| Supplemental cash flow information: | ||
| Interest paid | $— | $— |
| Supplemental disclosure of noncash financing activities: | ||
| Right-of-use asset obtained in exchange for new operating lease liability | $— | $219 |
| Issuance of Series C Preferred Stock conversion | $— | $23,313 |
| Conversion of Series C Preferred Stock | $129,825 | $— |
| Conversion of convertible note payable | $6,120 | $— |
| Assets acquired in connection with the reverse recapitalization | $17,222 | $— |
| Other liabilities assumed in connection with the reverse recapitalization | $9,459 | $— |
| Reverse recapitalization transaction costs included in accounts payable | $40 | $— |
| Concurrent Financing issuance costs included in accounts payable | $37 | $— |
| Concurrent Financing issuance costs paid by Reneo prior to Merger | $89 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.